Loading
Loading…
Loading…
| # | Company | Amount | Rank | Status |
|---|---|---|---|---|
| 1 | L1₹82.4 LAccepted-AOC THE CAPITAL 1802 1901 PLOT NO C 70 G BLOCK BANDRA KURLA COMPLEX BANDRA EAST MUMBAI MAHARASHTRA INDIA 400051 | MUMBAI | MUMBAI | MAHARASHTRA | 400051 | L1 | Accepted-AOC Details in notice | |
| 2 | L1Rejected-AOC 2ND FLOOR CABIN NO 2H SANOFI HOUSE CTS 11B SAKI VIHAR ROAD L T BUSINESS PARK POWAI MUMBAI MUMBAI MAHARASHTRA 400072 | MUMBAI SUBURBAN | MAHARASHTRA | 400072 | L1 | Rejected-AOC Details in notice | |
| 3 | L1Rejected-AOC 6TH FLOOR BUILDING NO 8 TOWER C DLF CYBER CITY PHASE II MOTI NAGAR GURGAON WEST DELHI DELHI 122002 | GURUGRAM | HARYANA | 122002 | L1 | Rejected-AOC Details in notice |
| Sl No | Description | Qty | Unit | TAKEDA BIOPHARMACEUTICALS INDIA PRIVATE LIMITED L2 | Sanofi Healthcare India Private Ltd L3 | Pfizer Products India Pvt. Ltd. L1 |
|---|---|---|---|---|---|---|
| 1.00 | LARONIDASE for Injection 2.9mg/5ml | 10 | VIAL | - | 47,986 ₹53,744.32 Lowest | - |
| 2.00 | IDURUSULFASE for IV use 6mg/3ml | 10 | VIAL | 1,24,000 ₹1,38,880 Lowest | - | - |
| 3.00 | AGALSIDASE BETA for IV use 35 mg | 10 | VIAL | - | 2,21,916 ₹2,33,011.8 Lowest | - |
| 4.00 | AGALSIDASE ALFA for IV use 3.5 mg | 10 | Litre | 90,000 ₹1,00,800 Lowest | - | - |
| 5.00 | RECOMBINANT HUMAN GROWTH HORMONE for injection
[Injectable pen with the needle]
• Recombinant growth hormone for daily injection
• Ready to use pen for subcutaneous injection
• Liquid/powder with reconstitution
• Needle for subcutaneous injection should be with the pen free of cost (minimum one needle per mg) (5mg pen with 5 needles)
• Should be available in different strengths
• Should be approved for GH deficiency, Turner syndrome, Noonan syndrome and prader willi syndrome by the government and international agencies. | 10,000 | Pen | - | - | 218.06 ₹218.06 Lowest |
Tender Value
Refer Docs
EMD Value
₹50,000
Closing Date
7 Oct 2024, 5:00 pmClosed
Managing Director
KMSCL, THYCAUD THIRUVANANTHAPURAM
E-TENDER FOR THE PROCUREMENT OF DRUGS FOR RARE DISEASES FOR THE YEAR 2024-25
2024_KMSCL_691176_1
KMSCL/ED/RD-SAT/RC/2024/019
Open Tender
Medicines
Item Wise
365 days
Thiruvananthapuram
Please refer tender document
19 documents required · 19 mandatory
₹29,500
Yes
₹50,000
Yes
1 Sept 2025
13 Sept 2024
8 Oct 2024
13 Sept 2024
7 Oct 2024
13 Sept 2024
13 Sept 2024 - 7 Oct 2024
LARONIDASE for Injection 2.9mg/5ml
IDURUSULFASE for IV use 6mg/3ml
AGALSIDASE BETA for IV use 35 mg
AGALSIDASE ALFA for IV use 3.5 mg
RECOMBINANT HUMAN GROWTH HORMONE for injection [Injectable pen with the needle] • Recombinant growth hormone for daily injection • Ready to use pen for subcutaneous injection • Liquid/powder with reconstitution • Needle for subcutaneous injection should be with the pen free of cost (minimum one needle per mg) (5mg pen with 5 needles) • Should be available in different strengths • Should be approved for GH deficiency, Turner syndrome, Noonan syndrome and prader willi syndrome by the government and international agencies.
TAKEDA BIOPHARMACEUTICALS INDIA PRIVATE LIMITED
Sanofi Healthcare India Private Ltd
stage.html
html • 0.04 MB
tech_bid_open.pdf
tech_eval.pdf
boq_comp_chart.xlsx
xlsx
fin_eval.pdf
aoc.pdf
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
html • 0.04 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .